RUBY News and Press, Rubius Therapeutics Inc. From 02/26/21

Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%,...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire CAMBRIDGE, Mass. , Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life science...

Rubius Therapeutics ([[RUBY]] -5.1%) reports Q4 net loss was $40.5M or $0.50 per share, compared to $44.5M or $0.56 last year same quarter.Company invested $25.6M in R&D related to its novel RED PLATFORM and towards expanding and advancing its product pipeline.G&A expenses were $14.1M...

Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia Screening Patients i...

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announce...

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood cells into medicines, called Red Cell Therapeutics™, for the treatment of cancer ...

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announce...

Rubius has an interesting science hypothesis, however it failed a first proof of concept trial. It is now running its next one. They have adequate cash for the time being. For further details see: Rubius: Watson, We Have No Data

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this event. For further details see: Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and Patient Screening Underway for Phase 1 Clinical Trial of RTX-321 in Advanced Hu...